Publications

Publications search (many options)

Publika data base

Publications (original articles or review articles) published in 2016 from OUS - Department of Gynaecological Oncology

25 publications found

Bjørge T, Skare GB, Bjørge L, Tropé A, Lönnberg S (2016)
Adverse Pregnancy Outcomes After Treatment for Cervical Intraepithelial Neoplasia
Obstet Gynecol, 128 (6), 1265-1273
PubMed 27824756

Davidson B, Kjæreng ML, Førsund M, Danielsen HE, Kristensen GB, Abeler VM (2016)
Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma
Am J Clin Pathol, 145 (4), 449-58
PubMed 27149024

Fjeldbo CS, Julin CH, Lando M, Forsberg MF, Aarnes EK, Alsner J, Kristensen GB, Malinen E, Lyng H (2016)
Integrative Analysis of DCE-MRI and Gene Expression Profiles in Construction of a Gene Classifier for Assessment of Hypoxia-Related Risk of Chemoradiotherapy Failure in Cervical Cancer
Clin Cancer Res, 22 (16), 4067-76
PubMed 27012812

Fjeldbo CS, Aarnes EK, Malinen E, Kristensen GB, Lyng H (2016)
Identification and Validation of Reference Genes for RT-qPCR Studies of Hypoxia in Squamous Cervical Cancer Patients
PLoS One, 11 (5), e0156259
PubMed 27244197

Gansmo LB, Bjørnslett M, Halle MK, Salvesen HB, Dørum A, Birkeland E, Hveem K, Romundstad P, Vatten L, Lønning PE, Knappskog S (2016)
The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian-but not endometrial cancer
Tumour Biol, 37 (8), 10697-702
PubMed 26867771

Gao B, Lindemann K, Anderson L, Fereday S, Hung J, Alsop K, Tothill RW, Gebski V, Kennedy C, Balleine RL, Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DD, DeFazio A (2016)
Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome
Gynecol Oncol, 142 (3), 458-64
PubMed 27444035

Grabowski JP, Harter P, Heitz F, Pujade-Lauraine E, Reuss A, Kristensen G, Ray-Coquard I, Heitz J, Traut A, Pfisterer J, du Bois A (2016)
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase
Gynecol Oncol, 140 (3), 457-62
PubMed 26807488

Lindemann K (2016)
Medical treatment of primary or recurrent cervical cancer
Int. J. Gynecol. Cancer, 26 1, 42-43

Lindemann K, Halaska MJ, Zalewski K (2016)
Surgical treatment of primary ovarian fallopian tube and peritoneal cancer
Int. J. Gynecol. Cancer, 26 1, 5-8

Lindemann K, Kristensen G, Mirza MR, Davies L, Hilpert F, Romero I, Ayhan A, Burges A, Rubio MJ, Raspagliesi F, Huizing M, Creemers GJ, Lykka M, Lee CK, Gebski V, Pujade-Lauraine E (2016)
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
Ann Oncol, 27 (8), 1505-10
PubMed 27407100

Lindemann K, Zalewski K, Halaska MJ, Lindquist D, The LiFE Team (2016)
Life - Literature for ENYGO
Int. J. Gynecol. Cancer, 26 4, 2-73

Lönnberg S, Andreassen T, Engesæter B, Lilleng R, Kleven C, Skare A, Johansson K, Fredheim CS, Tropé A (2016)
Impact of scheduled appointments on cervical screening participation in Norway: a randomised intervention
BMJ Open, 6 (11), e013728
PubMed 28186949

Makar AP, Tropé CG, Tummers P, Denys H, Vandecasteele K (2016)
Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer
Oncologist, 21 (6), 745-54
PubMed 27009938

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J et al. (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
N Engl J Med, 375 (22), 2154-2164
PubMed 27717299

Nymoen DA, Slipicevic A, Holth A, Emilsen E, Hetland Falkenthal TE, Tropé CG, Reich R, Flørenes VA, Davidson B (2016)
MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma
Hum Pathol, 54, 74-81
PubMed 27063471

Ruhlmann CH, Christensen TB, Dohn LH, Paludan M, Rønnengart E, Halekoh U, Hilpert F, Feyer P, Kristensen G, Hansen O, Keefe D, Herrstedt J (2016)
Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial
Lancet Oncol, 17 (4), 509-18
PubMed 26952945

Sert BM, Boggess JF, Ahmad S, Jackson AL, Stavitzski NM, Dahl AA, Holloway RW (2016)
Robot-assisted versus open radical hysterectomy: A multi-institutional experience for early-stage cervical cancer
Eur J Surg Oncol, 42 (4), 513-22
PubMed 26843445

Smogeli E, Davidson B, Cvancarova M, Holth A, Katz B, Risberg B, Kristensen G, Lindemann K (2016)
L1CAM as a prognostic marker in stage I endometrial cancer: a validation study
BMC Cancer, 16, 596
PubMed 27488577

Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E, AURELIA Investigators (2016)
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
Gynecol Oncol, 144 (1), 65-71
PubMed 27871723

Szczesny W, Vistad I, Kaern J, Nakling J, Tropé C, Paulsen T (2016)
Impact of hospital type and treatment on long-term survival among patients with FIGO Stage IIIC epithelial ovarian cancer: follow-up through two recurrences and three treatment lines in search for predictors for survival
Eur J Gynaecol Oncol, 37 (3), 305-11
PubMed 27352555

Tambe M, Pruikkonen S, Mäki-Jouppila J, Chen P, Elgaaen BV, Straume AH, Huhtinen K, Cárpen O, Lønning PE, Davidson B, Hautaniemi S, Kallio MJ (2016)
Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel
Oncotarget, 7 (11), 12267-85
PubMed 26943585

Trillsch F, Mahner S, Hilpert F, Davies L, García-Martínez E, Kristensen G, Savarese A, Vuylsteke P, Los M, Zagouri F, Gladieff L, Sehouli J, Khoon Lee C, Gebski V, Pujade-Lauraine E (2016)
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial
Ann Oncol, 27 (9), 1733-9
PubMed 27287207

Wiedmann MK, Brunborg C, Di Ieva A, Lindemann K, Johannesen TB, Vatten L, Helseth E, Zwart JA (2016)
The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study
Neuro Oncol (in press)
PubMed 28040713

Zalewski K, Lindemann K, Halaska MJ (2016)
Medical treatment of primary ovarian cancer
Int. J. Gynecol. Cancer, 26 1, 9-11

Zhou C, Clamp A, Backen A, Berzuini C, Renehan A, Banks RE, Kaplan R, Scherer SJ, Kristensen GB, Pujade-Lauraine E, Dive C, Jayson GC (2016)
Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
Br J Cancer, 115 (2), 228-35
PubMed 27351218